Director, Global Value and Health Economics and Outcomes Research

Jazz Pharmaceuticals•Philadelphia, PA

2d•$212,000 - $318,000•Remote

About The Position

The Director, Global Value and HEOR is a strategic and execution-oriented leadership role accountable for global and US payer evidence strategy across marketed assets in Jazz Pharmaceuticals’ neurology portfolio. The role supports brand potential, value defense, expanded access, and evidence generation throughout the post-launch lifecycle, including label expansions, new formulations, line extensions, and competitive market shifts. It operates across broad commercial disease areas and rare diseases, translating commercial, access, and policy priorities into methodologically sound evidence plans and deliverables such as updated global economic models, real-world observational studies, patient registries, Global Value Dossiers, and US AMCP dossiers. The Director serves as the dedicated US HEOR lead for assigned products, partnering with US Market Access, Pricing & Contracting, US Medical Affairs, and the Payer Field Team. The role also collaborates with the EU/INT HEOR team on HTA reassessment strategies and post-launch evidence packages. As a stakeholder in Integrated Evidence Generation Plan governance and brand strategy forums, the Director aligns post-marketing evidence initiatives with brand objectives and manages their execution. The role leads lifecycle management and label-expansion evidence strategies; supports payer-relevant endpoints and measures in late-phase and pragmatic studies; develops evidence to address rare-disease uncertainty; and creates strategies for value defense, HTA reassessments, and continued reimbursement. It directs US payer evidence and field enablement, ensures compliance of payer communications, contributes to innovative contracting and value-based agreements, and monitors US policy and value-assessment developments. It also leads economic modeling, cross-functional evidence governance, publications, vendor and budget oversight, and informal technical mentorship.

Requirements

Master’s degree (MSc, MS, MPH) or PhD in Health Economics, Outcomes Research, Pharmacoeconomics, or a closely related quantitative field.
Seven to ten years of experience in HEOR, Global Value, or Health Economics within the biopharmaceutical industry or a top-tier HEOR consulting firm.
Demonstrated experience leading HEOR strategy and executing evidence deliverables for marketed pharmaceutical products, including lifecycle management, label expansions, and value defense.
Launch lead for at least two assets as a US HEOR lead, or country-level HTA lead.
Deep understanding of US payers and population health decision-makers, including oncology pathways.
Proven technical expertise building, adapting, and validating economic models, including Markov, partitioned survival, microsimulation, and dynamic budget-impact models, using mature real-world and clinical-trial data.
Experience collaborating with US Market Access, Pricing/Contracting, and Payer Field Teams to develop customer-facing tools, interactive budget models, and AMCP dossiers under applicable US guidance.
Working knowledge of US and global healthcare databases such as IQVIA, Optum, MarketScan, Medicare SAF, disease-specific registries, and electronic health records, and of advanced epidemiological methods for comparative research.
Demonstrated understanding of rare-disease post-launch evidence challenges, including registry management, natural-history benchmarks, long-term surrogate endpoint validation, and specialized HTA reimbursement mechanisms.
Ability to work with regional HEOR teams, especially EU/INT, on HTA reassessment packages and local-market execution.
Ability to balance strategic evidence planning with hands-on execution of technical deliverables, including dossiers, models, observational research protocols, and publications.
Exceptional verbal, written, and presentation skills; ability to influence cross-functional teams without direct authority and defend methodologies before payers, HTA authorities, and scientific reviewers.

Nice To Haves

Experience with oncology assets.
Preferred experience in HEOR product leadership above the country level.
Experience serving as the US HEOR lead or driving US pre-launch HEOR deliverables, such as AMCP PIE dossiers, US budget-impact models, and payer field enablement, or significant exposure to these deliverables from a global role.
Experience conducting post-marketing real-world evidence research, patient registry studies, and economic evaluations in rare diseases, specialized medicine, or complex chronic conditions.
Substantial experience collaborating with regional HEOR teams on evidence packages for global HTA reassessments, renewals, or pricing renegotiations.
Strong peer-reviewed publication record in health economics and outcomes research.

Responsibilities

Lead HEOR evidence-generation strategies supporting supplemental regulatory filings for new indications, line extensions, expanded patient subpopulations, and novel delivery formulations or devices.
Partner with Medical Affairs, Clinical Development, and Biostatistics to incorporate payer-relevant comparative endpoints, patient-reported outcomes, and health-related quality-of-life measures into Phase 3b/4 protocols, pragmatic trials, and expanded-access programs.
Work with Market Access to evaluate evidence requirements across multi-indication product lifecycles and deliver comparative-effectiveness and economic evidence to support access after label expansions.
Collaborate on long-term prospective registries, natural-history extensions, and post-authorization safety and efficacy studies for rare-disease assets.
Identify competitive threats, standards-of-care shifts, and generic or biosimilar erosion; design and execute comparative-effectiveness, adherence, and burden-of-illness studies to support product differentiation and access positioning.
Partner with EU/INT HEOR colleagues on evidence strategies and analytical packages for HTA reassessments, conditional reimbursement reviews, and price renegotiations.
Design real-world data programs to fulfill post-launch evidence commitments and support conversion of conditional or temporary reimbursement to permanent access.
Direct maintenance and substantive updates of Global Value Dossiers, systematic literature reviews, and meta-analyses.
Serve as the designated US HEOR expert for assigned inline products and translate US brand and access priorities into health economic deliverables.
Lead the authoring, annual maintenance, and reactive dissemination of AMCP dossiers, unbranded value summaries, and state Medicaid submission dossiers.
Partner with the US Payer Field Team and US Medical Affairs to develop and train teams on customer-facing economic models and reactive scientific presentations.
Ensure US HEOR deliverables, economic models, and field materials comply with FDAMA Section 114, the 21st Century Cures Act, and FDA guidance on health care economic information.
Collaborate with US Market Access, Pricing, and Contracting to assess outcomes-based agreements and establish real-world endpoint tracking frameworks using claims or EHR data.
Monitor US health policy and develop evidence plans and materials for engagement with ICER and other value-assessment bodies.
Formulate and execute economic modeling strategies for marketed products, including cost-effectiveness, cost-utility, budget-impact, and cost-offset models.
Adapt early trial-based models into mature models incorporating long-term survival, real-world treatment patterns, dosing adherence, and observational utility weights.
Use appropriate modeling approaches to address uncertainty, treatment sequencing, treatment switching, and heterogeneous rare-disease patient trajectories.
Build transparent, user-friendly US commercial, Medicare Advantage, and state Medicaid budget-impact models with customizable formulary and market scenarios.
Represent GVHEOR in Integrated Evidence Generation Plan governance for inline assets and align post-marketing studies and budget milestones with brand objectives.
Work with Market Access to ensure payer evidence plans validate and update product value stories in response to real-world utilization and payer coverage shifts.
Partner with Medical Affairs, Commercial Brand Leads, Regulatory Affairs, Biostatistics, and RWE teams to align post-launch evidence initiatives.
Lead post-marketing HEOR publications, write and submit manuscripts, and present data at scientific congresses.
Manage project budgets and oversee external HEOR consultancies, academic partners, and contract research organizations.
Provide informal mentorship and technical guidance to associate directors, managers, and fellows.